Elesclomol (STA-4783)

製品コードS1052

Elesclomol (STA-4783)化学構造

分子量(MW):400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

サイズ 価格(税別)  
JPY 31540.00
JPY 28220.00
JPY 53120.00
JPY 161020.00

カスタマーフィードバック(4)

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

製品説明 Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
ターゲット
HSP70 [1]
(Cell-free assay)
体外試験

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell NUPnU49VT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnOSFhKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKDNwNk\lMVA2KM7:TR?= MnjLV2FPT0WU
CAL-51 cell M1qwUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHftfWRKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTJ4IH7N M3HDPHNCVkeHUh?=
ABC-1 cell MoTDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mm\nTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y2KG6P MX3TRW5ITVJ?
A2780 cell MmXlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;lOZpZUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTl2IH7N NWO0ZVJDW0GQR1XS
ES1 cell MlzJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlnmTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLke0PUBvVQ>? MWTTRW5ITVJ?
HUTU-80 cell NInxWGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIrrTmlKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd7MTDuUS=> NWPPRVJZW0GQR1XS
NCI-H292 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDZibl2= MoraV2FPT0WU
NB69 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYq2PFFNUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOiCwTR?= NGn5UYxUSU6JRWK=
ES8 cell M33Semdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVvJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{Kgcm0> NHjhZXdUSU6JRWK=
BCPAP cell NVLWVVhqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXi3UWZSUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2= M3foe3NCVkeHUh?=
T-24 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoHVTY5pcWKrdHnvckBw\iCqdX3hckBVNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61OUBvVQ>? MkjOV2FPT0WU
EW-16 cell M2LPfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2jXWWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyKG6P NWHMVllsW0GQR1XS
OVCAR-5 cell M{W0Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnOxTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?= M2i2e3NCVkeHUh?=
SF126 cell M{jXe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MU\Jcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65OUBvVQ>? NEDl[5pUSU6JRWK=
KP-4 cell NF6zeYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIXsSIVKdmirYnn0bY9vKG:oIHj1cYFvKEuSLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlE4KG6P NGHkRlFUSU6JRWK=
GAMG cell NGnYNZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4TRVWlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVEhdk1? NYDxN|k1W0GQR1XS
HOS cell Mnu2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1y1PWlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj61N{BvVQ>? NX7rS243W0GQR1XS
CHL-1 cell M2Xafmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFHU[pNKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?= Mlu1V2FPT0WU
AGS cell M4C2VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHO0WZhKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFYhdk1? MX\TRW5ITVJ?
MDA-MB-157 cell MnXmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{IH7N MmDmV2FPT0WU
HSC-3 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXnsU2trUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= NXjy[3I1W0GQR1XS
CAL-72 cell NYnlboFQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC15MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? NYS0ZYdnW0GQR1XS
NBsusSR cell NHG0em1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmTKTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOyCwTR?= M376SnNCVkeHUh?=
ES7 cell MmPmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGVUPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNUmgcm0> MoPaV2FPT0WU
H-EMC-SS cell NIXDXlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{L3NWlvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N NXTUcph{W0GQR1XS
NCI-H1703 cell NF;KVZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlrMTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N NVG1ZmU5W0GQR1XS
BHT-101 cell NVXYVWtsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1S5RmlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzJibl2= NFLqO2hUSU6JRWK=
SK-OV-3 cell NFnTZ|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmnnTY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44PSCwTR?= Mn3oV2FPT0WU
EW-24 cell NWPORoxwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\rUWRQUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDNibl2= NYn5TFRDW0GQR1XS
PSN1 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{DEVGlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFQhdk1? MYjTRW5ITVJ?
OVCAR-8 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{j6TGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2= MoHtV2FPT0WU
NCI-H1563 cell NEnibIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1LYUWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> MkXCV2FPT0WU
SW756 cell M2f3dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mkm1TY5pcWKrdHnvckBw\iCqdX3hckBUXzd3NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNVMhdk1? NFnwOIJUSU6JRWK=
A375 cell NYPCRXhST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUHubpp7UW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yPCCwTR?= NHPrWnZUSU6JRWK=
Ca9-22 cell M17TZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnJcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlUhdk1? NH;5SnFUSU6JRWK=
SW1990 cell NF7hV2pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTl7MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|Ihdk1? MWLTRW5ITVJ?
ES4 cell M2HYcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1\nTWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6zPUBvVQ>? NGXGU49USU6JRWK=
HCE-T cell M1HXfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHXBSnZKdmirYnn0bY9vKG:oIHj1cYFvKEiFRT3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PSCwTR?= NFPJRnpUSU6JRWK=
MOLT-16 cell NInmPHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlU{KG6P NXTweZkzW0GQR1XS
HSC-4 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mm\NTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPEBvVQ>? M2r5VXNCVkeHUh?=
NCI-SNU-1 cell NHzaOlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIXrdlRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOE[gcm0> MYfTRW5ITVJ?
EW-11 cell NEDlcVBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND65JI5O NIfydXVUSU6JRWK=
HT-1080 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2PPfGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlibl2= MV;TRW5ITVJ?
MES-SA/Dx5 cells M1S0RWN6fG:2b4jpZ4l1gSCjc4PhfS=> NET6O49EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzMEBKSzVyPUWgcm0> MljzNlM6Ozd7OEG=
SW1710 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGjLZYZKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2= M1\UfnNCVkeHUh?=
EW-1 cell M4PiWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFjl[I1KdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI1KG6P M{H0S3NCVkeHUh?=
BV-173 cell NE\QenNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEnWfFBKdmirYnn0bY9vKG:oIHj1cYFvKEKYLUG3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzlibl2= MWTTRW5ITVJ?
TE-8 cell NFfNUlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{DBcGlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFEhdk1? NYfxeW9KW0GQR1XS
G-401 cell MkDlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkeyTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFMhdk1? NYHRRlBvW0GQR1XS
KOSC-2 cell MnTqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWrycYxiUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR3IH7N NVzGZVhLW0GQR1XS
HuCCT1 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWDJcohq[mm2aX;uJI9nKGi3bXHuJGh2S0OWMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVIhdk1? NH7YbnBUSU6JRWK=
FADU cell M4TwWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEC5WXZKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P MYrTRW5ITVJ?
MHH-ES-1 cell NFXHW2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYPxb4tqUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkmgcm0> NEH4W3JUSU6JRWK=
ES3 cell MkDtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHzSc2lKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|khdk1? NF7GRZFUSU6JRWK=
OVCAR-4 cell NXu0XItJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg4KG6P MUTTRW5ITVJ?
HD-MY-Z cell NEfVfJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3TGUGlvcGmkaYTpc44hd2ZiaIXtZY4hUERvTWmtXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTFibl2= NVPBbVd7W0GQR1XS
human JAR cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYLYXZVRUW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk4KG6P M4fGdHNCVkeHUh?=
A427 cell NVf4RWROT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlXZTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6wO{BvVQ>? NFTHVWdUSU6JRWK=
697 cell NWryZW14T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwMUOgcm0> NV7RUW85W0GQR1XS
OVCAR-3 cell MmfMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFTnNXBKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjJibl2= MXnTRW5ITVJ?
human NB14 cell MmHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1LFWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOlQhdk1? NH;RTpZUSU6JRWK=
GB-1 cell M4\CbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37UVGlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uO|Ehdk1? MYrTRW5ITVJ?
COR-L105 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44PiCwTR?= MlzmV2FPT0WU
647-V cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWDJcohq[mm2aX;uJI9nKGi3bXHuJFY1Py2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj65JI5O Mn3HV2FPT0WU
human K5 cell NFvNfmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYnJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PyCwTR?= MlryV2FPT0WU
DMS-273 cell NGHtNmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NITVOFBKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N M1L1WHNCVkeHUh?=
UM-UC-3 cell MnXqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHja[YRKdmirYnn0bY9vKG:oIHj1cYFvKFWPLWXDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N M4jzdHNCVkeHUh?=
HEL cell NVTpSG1VT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEigcm0> NWr6N25pW0GQR1XS
human KU-19-19 cell Mnq2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYPFZ4hbUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> NFvDUZFUSU6JRWK=
MC-IXC cell NV;0UoozT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYjJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNVchdk1? MYPTRW5ITVJ?
human H4 cell MmDyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV:ydZdLUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNlUhdk1? M1\EOXNCVkeHUh?=
NUGC-3 cell NILKXoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJG5WT0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuN|Mhdk1? M{TYXnNCVkeHUh?=
CHP-212 cell NF\GZlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM1KG6P M3;UNHNCVkeHUh?=
human SW982 cell NWjSXXMxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFPBUVVKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?= NUX2W25SW0GQR1XS
C-33-A cell NEfrTm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGMuOzNvQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVghdk1? M4HJSXNCVkeHUh?=
PC-3 cell NX\lV|R5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH3JeldKdmirYnn0bY9vKG:oIHj1cYFvKFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg6KG6P MkmyV2FPT0WU
COLO-684 cell NFfJO|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnK1TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2= NVvlWJVpW0GQR1XS
SNU-387 cell M3rSTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV7XTox{UW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QS52OTDuUS=> Mkm5V2FPT0WU
U251 cell NEjZ[pFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2JI5O MnfBV2FPT0WU
A673 cell NVjZTVFsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mk\xTY5pcWKrdHnvckBw\iCqdX3hckBCPjd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuOkBvVQ>? MX;TRW5ITVJ?
human T47D cell NX7TeIp{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWDlOmJsUW6qaXLpeIlwdiCxZjDoeY1idiCWNEfEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzlibl2= NX\BcVRNW0GQR1XS
A549 cell M2HFd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX[wOXhlUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPiCwTR?= NYjYdG9zW0GQR1XS
PC-14 cell NWrxeohxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mli1TY5pcWKrdHnvckBw\iCqdX3hckBRSy1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0Mlc{KG6P MX7TRW5ITVJ?
A704 cell NEPpd25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoT2TY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkeuOFUhdk1? NE\rOlVUSU6JRWK=
MCF7 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkTOTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{GuN|Yhdk1? NG\PemdUSU6JRWK=
PC3 cells M3vNW2Z2dmO2aX;uJIF{e2G7 NH76VmVKdmirYnn0bY9vKG:oIGDET|EudWWmaXH0[YQhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhicnXzbYR2\SCrbjDoeY1idiCSQ{OgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC5zMUOg{txO NYfCVWtIOjF|NEG2O|U>
F-36P cells NG\pT3JRem:uaX\ldoF1cW:wIHHzd4F6 MnXmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCILUO2VEBk\WyuczygTWM2OD1yLkK4JO69VQ>? NYDUbXg4OjF|NEG2O|U>
OCI-AML2 cells MYHQdo9tcW[ncnH0bY9vKGG|c3H5 M2TqfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT1PJMWFOVDJiY3XscJMtKEmFNUC9NE4{PSEQvF2= M4i5cVIyOzRzNke1
K562 cells NIq0U4hRem:uaX\ldoF1cW:wIHHzd4F6 MmTrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|LDDJR|UxRTF6IN88US=> NUL6e|NWOjF|NEG2O|U>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: Hs294T, HSB2, and Ramos
  • 濃度: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • 反応時間: 18, or 24 hours
  • 実験の流れ: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~100 mg/kg
  • 投与方法: Intravenous injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
1% DMSO+30% polyethylene glycol+1% Tween 80
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 400.5
化学式

C19H20N4O2S2

CAS No. 488832-69-5
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 13 2010 Phase 2
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 13 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How can we use the compound for in vivo mouse studies?

  • 回答:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90)シグナル伝達経路

相関HSP (e.g. HSP90)製品

Tags: Elesclomol (STA-4783)を買う | Elesclomol (STA-4783) ic50 | Elesclomol (STA-4783)供給者 | Elesclomol (STA-4783)を購入する | Elesclomol (STA-4783)費用 | Elesclomol (STA-4783)生産者 | オーダーElesclomol (STA-4783) | Elesclomol (STA-4783)化学構造 | Elesclomol (STA-4783)分子量 | Elesclomol (STA-4783)代理店
×

大阪市内で「G20サミット」が開催されることに伴い、大阪府内で大規模な交通規制が行われる影響で、6月26日(水)から7月1日(月)までの間、下記地域へ出荷が行えなくなります。
対象地域
大阪府(全域)、兵庫県(芦屋市、尼崎市、伊丹市、西宮市)
上記地域より西の地域につきましては納期の遅延が予想されます。
また、国際便も遅延が予想されているため国内在庫がない製品の納期が一週間程度遅れる可能性がございます。
ご不便をおかけいたしますが、宜しくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID